BMJ open
May 11, 2026
Julia Colcott, Alexandre A Guerin, Olivia Carter et al.
A new tool, the MDMA-Assisted Psychotherapy Side Effects Tool (M-SET), was developed to systematically capture side effects during MDMA-assisted psychotherapy. Experts in MDMA-AP and neuropsychopharmacology participated in a two-round online Delphi process to refine a list of 165 items across four questionnaires covering screening, baseline, medication session days, and follow-up. The tool aims to improve safety monitoring and build a more robust evidence base on the tolerability of MDMA-AP for research and clinical use.
Imaging neuroscience (Cambridge, Mass.)
January 1, 2024
Hanna Molla, Giovanni Novembre, Anya Bershad et al.
MDMA increases the perceived pleasantness of touch, but the neural mechanisms are not well understood. In a double-blind, randomized, within-subject fMRI study with 18 healthy participants, MDMA (1.5 mg/kg) compared to placebo enhanced affective ratings of gentle touch at both a slower, more pleasant speed (3 cm/s) and a faster, less pleasant speed (30 cm/s). Plasma oxytocin levels also increased more during the MDMA session. On the neural level, primary sensorimotor areas showed greater hemodynamic changes during MDMA for both touch speeds, indicating an early influence within somatosensory pathways. Changes in oxytocin levels interacted with the drug in area MT+, associated with motion perception. However, the posterior insula did not show preferential activation for the slower stroking speed.